Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Identification and Analysis of Shared Risk Factors in Sepsis and High Mortality Risk COVID-19 Patients

Sayoni Das, Krystyna Taylor, Matthew Pearson, James Kozubek, Marcin Pawlowski, Claus Erik Jensen, Zbigniew Skowron, Gert Lykke Møller, Mark Strivens, Steve Gardner
doi: https://doi.org/10.1101/2020.05.05.20091918
Sayoni Das
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krystyna Taylor
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Pearson
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Kozubek
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcin Pawlowski
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claus Erik Jensen
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zbigniew Skowron
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gert Lykke Møller
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Strivens
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Gardner
1PrecisionLife Ltd, Long Hanborough, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: steve@precisionlife.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND Coronavirus disease 2019 (COVID-19) is a novel coronavirus strain disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease is highly transmissible and severe disease including viral sepsis has been reported in up to 16% of hospitalized cases. The admission characteristics associated with increased odds of hospital mortality among confirmed cases of COVID-19 include severe hypoxia, low platelet count, elevated bilirubin, hypoalbuminemia and reduced glomerular filtration rate. These symptoms correlate highly with severe sepsis cases. The diseases also share similar comorbidity risks including dementia, type 2 diabetes mellitus, coronary heart disease, hypertension and chronic renal failure. Sepsis has been observed in up to 59% of hospitalized COVID-19 patients.

It is highly desirable to identify risk factors and novel therapy/drug repurposing avenues for late-stage severe COVID-19 patients. This would enable better protection of at-risk populations and clinical stratification of COVID-19 patients according to their risk for developing life threatening disease.

METHODS As there is currently insufficient data available for confirmed COVID-19 patients correlating their genomic profile, disease severity and outcome, co-morbidities and treatments as well as epidemiological risk factors (such as ethnicity, blood group, smoking, BMI etc.), a direct study of the impact of host genomics on disease severity and outcomes is not yet possible. We therefore ran a study on the UK Biobank sepsis cohort as a surrogate to identify sepsis associated signatures and genes, and correlated these with COVID-19 patients.

Sepsis is itself a life-threatening inflammatory health condition with a mortality rate of approximately 20%. Like the initial studies for COVID-19 patients, standard genome wide association studies (GWAS) have previously failed to identify more than a handful of genetic variants that predispose individuals to developing sepsis.

RESULTS We used a combinatorial association approach to analyze a sepsis population derived from UK Biobank. We identified 70 sepsis risk-associated genes, which provide insights into the disease mechanisms underlying sepsis pathogenesis. Many of these targets can be grouped by common mechanisms of action such as endothelial cell dysfunction, PI3K/mTOR pathway signaling, immune response regulation, aberrant GABA and neurogenic signaling.

CONCLUSION This study has identified 70 sepsis related genes, many of them for the first time, that can reasonably be considered to be potentially relevant to severe COVID-19 patients. We have further identified 59 drug repurposing candidates for 13 of these targets that can be used for the development of novel therapeutic strategies to increase the survival rate of patients who develop sepsis and potentially severe COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

All work was funded by PrecisionLife Ltd. No payments were received from any external/third party funding source.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data will be made available in supplemental files in future versions of this paper and can be obtained by emailing covid-19@precisionlife.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted May 09, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Identification and Analysis of Shared Risk Factors in Sepsis and High Mortality Risk COVID-19 Patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Identification and Analysis of Shared Risk Factors in Sepsis and High Mortality Risk COVID-19 Patients
Sayoni Das, Krystyna Taylor, Matthew Pearson, James Kozubek, Marcin Pawlowski, Claus Erik Jensen, Zbigniew Skowron, Gert Lykke Møller, Mark Strivens, Steve Gardner
medRxiv 2020.05.05.20091918; doi: https://doi.org/10.1101/2020.05.05.20091918
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Identification and Analysis of Shared Risk Factors in Sepsis and High Mortality Risk COVID-19 Patients
Sayoni Das, Krystyna Taylor, Matthew Pearson, James Kozubek, Marcin Pawlowski, Claus Erik Jensen, Zbigniew Skowron, Gert Lykke Møller, Mark Strivens, Steve Gardner
medRxiv 2020.05.05.20091918; doi: https://doi.org/10.1101/2020.05.05.20091918

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4810)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5280)
  • Intensive Care and Critical Care Medicine (326)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (110)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (438)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (127)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (768)
  • Public and Global Health (1798)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (68)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)